Cost containment and improving ways of treating people are key drivers for healthcare systems. Unfortunately, these do not often go hand in hand. Finding novel therapeutics with enhanced efficacy is both time consuming and costly.
To help combat decades of stagnation in antibiotic development, a team led by the National Physical Laboratory conducted two studies into the antimicrobial peptides that fight infection in our bodies and the feasibility of using them as the basis for new antibiotic treatment which is less prone to bacterial resistance.
Todayâs information technologies profoundly affect the way we conduct research and development (R&D), and the last 20 years have seen great advances in information technology across both our work and home lives.
When it comes to DNA research, scientists often find themselves weighing digital PCR (dPCR) against the more established quantitative real-time PCR (qPCR). Which technique is better to use? The answer is both.
By Dr Y. John Shyu, Dr Katherine E. Strathearn and Dr Richard M. Eglen
Recently, pre-clinical and clinical studies of stem cells in regenerative medicine have demonstrated great promise as treatments for various diseases. Their ability to self-renew and differentiate makes stem cells valuable for both cell therapy and tissue engineering fields, both of which drive the demand for largescale cell expansion.
Drug discovery in the last few decades has focused on the cellular and genetic mechanisms of disease. This has been very successful in cancer, which is a disease of somatic genetics, and moderately successful elsewhere.
Rigaku is pleased to announce the release of the nano3DX X-ray microscope, which debuted at ACMM23 & ICONN2014 (the 23rd Australian Conference on Microscopy and Microanalysis and the International Conference on Nanoscience and Nanotechnology).